Announcement of Progress on Share Repurchase
Securities Code: 301093
Securities Abbreviation: Hualan Co., Ltd.
Announcement No.: 2026-043
Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions.
The Company held the second meeting of the sixth Board of Directors on June 23, 2025, where it reviewed and approved the proposal on using overraised funds, own funds, and self-raised funds to repurchase company shares via centralized bidding. This proposal was subsequently reviewed and approved item by item at the third extraordinary general meeting of shareholders held on July 11, 2025. For specific details, please refer to the repurchase report disclosed by the Company on July 12, 2025, on the Giant Tide Information Network (www.cninfo.com.cn).
According to the repurchase report, the Company will use overraised funds, own funds, and self-raised funds to repurchase company shares via centralized bidding. The total amount for the repurchase will not be less than RMB 100 million (inclusive) and not exceed RMB 200 million (inclusive), with overraised funds not less than RMB 30 million (inclusive) and not exceeding RMB 60 million (inclusive), and own funds and self-raised funds not less than RMB 70 million (inclusive) and not exceeding RMB 140 million (inclusive). The repurchase price will not exceed RMB 45.50 per share (inclusive), and the repurchase period will be no more than 12 months from the date of approval by the shareholders' meeting.
Upon completion of the repurchase, the shares will be used for cancellation and reduction of the Company's registered capital, as well as for employee stock ownership plans or equity incentives. Shares repurchased with overraised funds will be legally canceled and will reduce the Company's registered capital, while shares repurchased with own funds and self-raised funds will be used for employee stock ownership plans or equity incentives at an appropriate future time.